Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 14, 2014, Pages 5301-5306

  Ali, Youssif Mohammed ^a,b   Hayat, Azam ^a,c   Saeed, Bayad Mawlood ^a   Haleem, Kashif S ^a,c   Alshamrani, Saleh ^a,d   Kenawy, Hany I ^a,b   Ferreira, Viviana P ^e   Saggu, Gurpanna ^e   Buchberger, Anna ^a,f   Lachmann, Peter J ^f   Sim, Robert B ^a   Goundis, Dimitrios ^g   Andrew, Peter W ^a   Lynch, Nicholas J ^a   Schwaeble, Wilhelm J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b MANSOURA UNIVERSITY   (Egypt)

^c HAZARA UNIVERSITY   (Pakistan)

^d NAJRAN UNIVERSITY   (Saudi Arabia)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MEDICINES COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; IRON DEXTRAN; PROPERDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL LOAD; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; LOW DRUG DOSE; MENINGOCOCCOSIS; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEPSIS; SINGLE DRUG DOSE; SURVIVAL TIME; WILD TYPE;

ANIMALS; BACTERIAL VACCINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MENINGOCOCCAL INFECTIONS; MICE; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTIONS; PROPERDIN; RECOMBINANT PROTEINS;

EID: 84898035332     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401011111     Document Type: Article

References (48)

1. Kyaw MH, et al. (2003) Invasive pneumococcal disease in Scotland, 1999-2001: Use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 37(10):1283-1291.
2. Miller E, et al. (2000) Epidemiology of invasive and other pneumococcal disease in children in England and Wales, 1996-1998. Acta Paediatr Suppl 89(435):11-16.
3. Neill DR, et al. (2012) T regulatory cells control susceptibility to invasive pneumococcal pneumonia in mice. PLoS Pathog 8(4):e1002660.
4. Ibarz-Pavón AB, et al. (2011) Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural Mozambique. PLoS ONE 6(6):e19717.
5. World Health Organization (2001) Weekly Epidemiological Record No. 1. Available at http://www.who.int/docstore/wer/pdf/2001/wer7637.pdf. Accessed October 2010
6. Boulton J (2013) Meninigitis immunisation: Challenges, successes and new developments. Br J Nurs 22(1):20-25.
7. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364(9431):365-367.
8. Ali YM, et al. (2012) The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog 8(7): e1002793.
9. Brown JS, et al. (2002) The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci USA 99(26):16969-16974.
10. Sprong T, et al. (2006) Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 107(12):4865-4870.
11. Kugelberg E, Gollan B, Tang CM (2008) Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine 26(Suppl 8):I34-I39.
12. Späth PJ, et al. (1999) Properdin deficiency in a large Swiss family: Identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 118(2):278-284.
13. Linton SM, Morgan BP (1999) Properdin deficiency and meningococcal disease-identifying those most at risk. Clin Exp Immunol 118(2):189-191.
14. Arlaud GJ, et al. (2002) Structural biology of the C1 complex of complement unveils the mechanisms of its activation and proteolytic activity. Mol Immunol 39(7-8): 383-394.
15. Carroll MV, Sim RB (2011) Complement in health and disease. Adv Drug Deliv Rev 63(12):965-975.
16. Lachmann PJ (2009) The amplification loop of the complement pathways. Adv Immunol 104:115-149.
17. Thurman JM, Holers VM (2006) The central role of the alternative complement pathway in human disease. J Immunol 176(3):1305-1310.
18. Mueller-Ortiz SL, Drouin SM, Wetsel RA (2004) The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect Immun 72(5): 2899-2906.
19. Stover CM, et al. (2008) Properdin plays a protective role in polymicrobial septic peritonitis. J Immunol 180(5):3313-3318.
20. Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4(3):359-395.
21. Söderström C, Braconier JH, Danielsson D, Sjöholm AG (1987) Bactericidal activity for Neisseria meningitidis in properdin-deficient sera. J Infect Dis 156(1):107-112.
22. Braconier JH, Odeberg H, Sjöholm AG (1983) Granulocyte phagocytosis of Streptococcus pneumoniae in properdin-deficient serum. Infect Immun 40(1):219-224.
23. Schejbel L, Rosenfeldt V, Marquart H, Valerius NH, Garred P (2009) Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome. Clin Immunol 131(3):456-462.
24. Farries TC, Lachmann PJ, Harrison RA (1988) Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. Biochem J 253(3):667-675.
25. Fearon DT, Austen KF (1975) Properdin: Binding to C3b and stabilization of the C3bdependent C3 convertase. J Exp Med 142(4):856-863.
26. Pillemer L, et al. (1954) The properdin system and immunity, I: Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120(3112):279-285.
27. Schwaeble WJ, Reid KB (1999) Does properdin crosslink the cellular and the humoral immune response? Immunol Today 20(1):17-21.
28. Whaley K (1980) Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med 151(3):501-516.
29. Wirthmueller U, et al. (1997) Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol 158(9):4444-4451.
30. Schwaeble W, et al. (1993) Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. J Immunol 151(5): 2521-2528.
31. Smith CA, Pangburn MK, Vogel CW, Müller-Eberhard HJ (1984) Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem 259(7):4582-4588.
32. Pangburn MK (1989) Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J Immunol 142(1):202-207.
33. Ferreira VP, Cortes C, Pangburn MK (2010) Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology 215(11):932-940.
34. Higgins JM, Wiedemann H, Timpl R, Reid KB (1995) Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats: Identification of modules important for function. J Immunol 155(12):5777-5785.
35. Schwaeble W, et al. (1987) Human complement factor H: Expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol 17(10):1485-1489.
36. Malito E, et al. (2013) Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci USA 110(9): 3304-3309.
37. Meri T, et al. (2013) Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 9(4):e1003308.
38. Agarwal S, et al. (2010) An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J Immunol 185(1): 507-516.
39. Farries TC, Finch JT, Lachmann PJ, Harrison RA (1987) Resolution and analysis of "native" and "activated" properdin. Biochem J 243(2):507-517.
40. Kemper C, Mitchell LM, Zhang L, Hourcade DE (2008) The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci USA 105(26):9023-9028.
41. Harboe M, et al. (2012) The role of properdin in zymosan-and Escherichia coliinduced complement activation. J Immunol 189(5):2606-2613.
42. Ali YM, et al. (2013) Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae. PLoS ONE 8(12):e82583.
43. Densen P, Weiler JM, Griffiss JM, Hoffmann LG (1987) Familial properdin deficiency and fatal meningococcemia: Correction of the bactericidal defect by vaccination. N Engl J Med 316(15):922-926.
44. Nielsen HE, Koch C, Magnussen P, Lind I (1989) Complement deficiencies in selected groups of patients with meningococcal disease. Scand J Infect Dis 21(4):389-396.
45. Kadioglu A, et al. (2000) Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 68(2):492-501.
46. Estabrook MM, Griffiss JM, Jarvis GA (1997) Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun 65(11):4436-4444.
47. Bayliss CD, et al. (2008) Neisseria meningitidis escape from the bactericidal activity of a monoclonal antibody is mediated by phase variation of lgtG and enhanced by a mutator phenotype. Infect Immun 76(11):5038-5048.
48. Wölbeling F, et al. (2011) Lung function and inflammation during murine Pseudomonas aeruginosa airway infection. Immunobiology 216(8):901-908.